IOVANCE BIOTHERAPEUTICS INC (IOVA)
Health Care · Cell therapy and cellular immunotherapy for oncology · NASDAQ
Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation.
What IOVANCE BIOTHERAPEUTICS INC does
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. The company manufactures individualized T cell therapies using centralized, scalable, and proprietary processes that rejuvenate and multiply each patient's polyclonal T cells into the billions. Iovance's lead commercial product is Amtagvi (lifileucel), the first one-time individualized T cell therapy approved for previously treated advanced melanoma in the U.S. and Canada, administered alongside lymphodepletion and Proleukin (aldesleukin). The company is expanding its pipeline with registrational trials in frontline advanced melanoma, previously treated advanced non-small cell lung cancer, and undifferentiated pleomorphic sarcoma/dedifferentiated liposarcoma.
Themes: ["TIL cell therapy / cellular immunotherapy","Advanced melanoma treatment","Personalized / individualized cancer medicine","Solid tumor oncology","Non-small cell lung cancer (NSCLC)","Sarcoma treatment"]
Fundamentals
- Price$4.37 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+119.6% as of 2026-07-09 close
- Net margin-123.9% as of 2026-07-10
- Gross margin+36.7% as of 2026-07-10
- ROE-50.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+34.3% as of 2026-07-10
- Revenue CAGR (3y)+1388.7% SEC XBRL
- Beta0.70 as of 2026-07-10
Key risks (from latest filing)
["Regulatory pathway challenges - company has withdrawn initial marketing authorization applications in EU (July 2025) and UK (May 2026) and is working to resubmit, indicating potential clinical or commercial viability concerns","Manufacturing and supply chain complexity - TIL therapy requires individualized, centralized manufacturing at authorized treatment centers, creating operational, scalability, and cost challenges","Clinical and commercial execution risk - company is unprofitable (-123.9% net margin) with high operating costs, and success depends on adoption across multiple authorized treatment centers and patient populations"]
Competitors & peers
- Kymriah (Novartis) - CAR-T cell therapy
- Yescarta (Gilead/Kite) - CAR-T cell therapy
- Bristol Myers Squibb - checkpoint inhibitors and cell therapies in oncology
- Merck - anti-PD-1 immunotherapies
- Roche - cancer immunotherapies and checkpoint inhibitors
- Juno Therapeutics (Celgene/BMS) - cell therapies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.